the Prudent Speculator

MARKET COMMENTARY MONDAY, JANUARY 8, 2018

EXECUTIVE SUMMARY

Happy New Year! - Best First Week Since 2006

Dow 25000 - Still Holding BA and CAT

Returns Race - Growth Off to A Fast Start

The Case for Value Part 1 - Returns Since 1927 and Since 2000

The Case for Value Part 2 - Rising Interest & Inflation Rates

The Case for Value Part 3 - Relative Metrics

The Case for Value Part 4 - Super Bullish AAII Sentiment


Company News - Updates on INTC, AGU/NTR & WBA

Market Review

Happy New Year, indeed! 2018 is off to a terrific start as the Nasdaq Composite Index and Dow Jones Industrial Average turned in their best first week in twelve years, with the Dow eclipsing the 25000 mark for the first time, a little more than one month after busting through 24000.



Though it is an antiquated price-weighted index where Boeing is eight times more important than Pfizer, despite the latter having greater market capitalization, major milestones for the Dow Jones Industrial Average will always attract investor attention. Only 11000 more points (44%) to go before James K. Glassman will be proven correct!





Happily, we own the top two Dow performers over the last 1000 point move, with **Boeing** (BA - \$308.84) and **Caterpillar** (CAT - \$161.96) both rallying on Friday to highs above our previously published Target Prices. For the time being, we are continuing to hold each, having raised our fair valuation assessment for the commercial aviation and defense concern to \$322 and for the maker of construction equipment to \$167.

Shares of Boeing surged anew after the company reportedly reached a deal to buy Brazilian aircraft maker Embraer for \$28 per share. The agreement, which has not been signed by either party, is expected to receive heavy regulatory scrutiny from the Brazilian government. The companies, via a December 21 press release, confirmed the talks, jointly stating, "The Boeing Company and Embraer confirmed the two companies are engaged in discussions regarding a potential combination, the basis of which remains under discussion...Any transaction would be


subject to the approval of the Brazilian government and regulators, the two companies' boards and Embraer's shareholders."

With strong competition in the small regional aircraft space between Mitsubishi, Sukhoi, Bombardier and Embraer, and no choices for BA customers to buy in-house models, we think a deal has potential benefits for BA. However, we aren't hanging our hat on any specific outcome just yet, as we think that the Brazilian government, which is a majority Embraer stakeholder, might play a significant role in the direction of the negotiations. Of course, we are pleased with Boeing's massive existing aircraft order book, while we like the defense side of the business, given the state of affairs around the world, and it doesn't hurt that the company's effective tax rate the last two quarters was 29% to 30%.

We are keeping close watch on Caterpillar, but we are still comfortable with our position in the stock, given the improving global economic outlook, the rise in commodity prices, the potential for increased infrastructure spending and the company's low effective tax rate. We also heard last week from the Commerce Department that construction spending in the U.S. rose 0.8% in November, better than the 0.6% projection.

Earnings for CAT are likely to soar over the next few years, with current consensus EPS estimates for 2017, 2018 and 2019 standing at \$6.46, \$7.95 and \$9.26, respectively, up from \$3.26 in 2016. Of course, we understand that Caterpillar is a cyclical company with the time to sell often when conditions look great and the time to buy when the future looks bleak, so our grip on the shares won't stay tight forever.

Though they were definitely on the Value side of the ledger when we initially recommended BA at \$118.18 less than two years ago and CAT at \$69.52 just prior to the Financial Crisis, it is not easy to call either a Value stock today, given that the former is trading at 32 times trailing earnings and the latter at a current P/E of 29. Still, given that the overall metrics on our newsletter portfolios remain much more reasonable than many of the Value indexes,...




As of 01.06.18. Weights based on model portfolios. Harmonic mean used to calculate the portfolio price metrics. Companies with negative earnings are excluded from the P/E and Estimated P/E calculations. SOURCE: Al Frank using data from Bloomberg

the Prudent Speculator

...we like the balance the duo offer our other much less expensive portfolio holdings, while we think that upside remains, especially in a market that has been fixated on Growth.

Alas, though our newsletter portfolios managed excellent gains north of 2.3%, the Value indexes brought up the rear again over the first four trading days of 2018...





...begging the question of when, and even if, we will see Value outperform again.

No doubt, it is much easier today (newsletter portfolio returns were north of 17% in 2017) to keep the faith that our way of investing is the best path to long-term success...



Inexpensive stocks, generally no matter how the valuation metrics are sliced and diced, have produced the best long-term returns...





...than it was back in the late 90's, the last and only other time that Value has lagged in the tenyear returns race. After all, TPS Portfolio returned 1.6% in 1998, versus a 28.6% return for the

S&P 500, while the newsletter trailed the S&P return by more than five full percentage points in 1999.

We did not waver back then in our belief that our broadly diversified portfolios of undervalued stocks would prove to be rewarding in the fullness of time, so we certainly have no reason to change our tune today, especially considering that big Info Tech companies Alphabet (aka Google) with a two-class-combined 70 basis point contribution to total return, Facebook (62 bps) and Visa (30 bps), as well as Consumer Discretionary titan Amazon (72 bps), accounted for most, if not all, of our return gap in 2017 versus the Russell 3000 index.

That said, we understand that we always will be judged against a benchmark, but the Value of our service often lies more in our ability to keep investors on track to achieving their long-term objectives. It doesn't matter how well our stocks or the indexes perform if an account is sitting in cash. In fact, few come close to equaling long-term index returns as they move in and out of equities, often at the wrong time.



	Investor	Returns	Index R	eturns	Differences		
	Equity Funds	Fixed Income Funds	S&P 500	Barclays Aggregate	Stocks	Bonds	
30 Year	3.98%	0.57%	10.16%	6.34%	-6.18%	-5.779	
20 Year	4.79%	0.48%	7.68%	5.29%	-2.89%	-4.819	
10 Year	3.64%	0.40%	6.95%	4.34%	-3.31%	-3.949	
5 Year	9.83%	0.05%	14.66%	2.23%	-4.83%	-2.189	
3 Year	3.42%	-0.23%	8.87%	3.03%	-5.45%	-3.269	
1 Year	7.26%	1.23%	11.96%	2.65%	-4.70%	-1.429	

push against media negativism from January to the end of the year. They were largely sellers in the second half of the year, either from fear or an attempt to find the top of the market. That top did not come in 2016 and investors paid for it.' said Cory Clark, Director at DALBAR, Inc."—DALBAR 4.4.17

Not surprisingly, the winner in the returns race varies from year to year – Value won in 2016 – and we hope that perspective can be had by considering that Value has convincingly won the long-term performance derby by a wide margin. More importantly, perhaps, given concerns about elevated stock market valuations today, we like how Value has performed since the last Growth stock peak...

the Prudent Speculator



Year	Year-by-Year Russell Returns									
	Russell 3000	Russell 3000	Russell 3000							
Year	Value	Growth	Index							
2017	13.17	29.58	21.12							
2016	18.38	7.38	12.72							
2015	-4.14	5.09	0.47							
2014	12.69	12.44	12.55							
2013	32.72	34.22	33.57							
2012	17.55	15.21	16.42							
2011	-0.10	2.18	1.03							
2010	16.22	17.62	16.92							
2009	19.71	36.95	28.29							
2008	-36.27	-38.46	-37.32							
2007	-1.05	11.50	5.17							
2006	22.32	9.42	15.68							
2005	6.82	5.15	6.10							
2004	16.93	6.91	11.94							
2003	31.10	30.97	31.04							
2002	-15.19	-28.02	-21.54							
2001	-4.32	-19.61	-11.44							
2000	8.04	-22.42	-7.30							
Annualized	7.18	4.15	5.86							
	Source: Bloomber	a and FTSE Russe	·II.							

Value doesn't always win the shortterm battles, as the trouncing inflicted by Growth this year attests, but it has handily won the long-term wars since both 1999 and 1927.

	Annualized Return	Standard Deviation
Value Stocks	13.3%	26.0%
Growth Stocks	9.3%	21.5%
Dividend Paying Stocks	10.5%	18.1%
Non-Dividend Paying Stocks	8.7%	29.7%
Long-Term Corporate Bonds	6.0%	7.5%
Long-Term Gov't Bonds	5.5%	8.5%
Intermediate Gov't Bonds	5.1%	4.4%
Treasury Bills	3.4%	0.9%
Inflation	3.0%	1.8%
sem 06.30.27 through 08.31.17. Growth stocks on the stocks of 0% small value and 507 pp of dividend payers, 40% of middle dividend payers, 40% of middle dividend payers stocks that do not pay a discosciates SBBI US IT Gory Tola Referm index. Intermediate IDEBIU US IT GovT Total Referm index. Intermediate BBIU US IT GovT of 18 Referm index. Intermediate that the stock of 18 Refermediate IDEBIU US IT GOVT OTAL Referme index. Fressory bills that Referm index. Inflation represented by the IDEBIU US IT GOVT OTAL RESEARCH INTERMEDIATE INT	6 large value returns rebalanced i yers, and 30% bottom of dividen ridend. Long term corporate bond ong term government bonds repri- e term government bonds represe i represented by the Ibbotson Assi- botson Associates SBBI US Inflat	monthly. Dividend payers = 30% d payers rebalanced monthly. is represented by the libbotson seented by the libbotson Associate need by the libbotson Associates ociates SBBI US 30 Day TBill tion index. SOURCE: All Frank


...with some suggesting that current investor infatuation with high-flying tech names looks a lot like what was happening right before the air began to come out of the Tech Bubble in the year 2000.



The tech stocks that dominated the NASDAQ Composite Index back in 2000 were hardly inexpensive from a fundamental standpoint.

	Weighting	Price to	Price to	Price to	Dividend
Company	Percentage	Earnings	Sales	Book Value	Yield
Microsoft	8.0	56.2	21.1	13.1	-
Cisco Systems	7.2	200.4	37.3	29.0	-
Intel	6.2	51.0	13.4	12.1	0.
Oracle	3.7	152.7	24.7	59.8	-
Sun Micro	2.4	122.7	11.6	28.6	-
MCI Worldcom	2.1	34.5	3.5	2.5	-
Dell	2.0	72.4	5.0	24.2	-
Yahoo	1.5	666.4	161.1	78.2	-
Qualcomm	1.3	159.5	18.9	24.1	-
Applied Materials	1.1	94.7	16.1	15.5	-
Averages:	3.6	161.1	31.3	28.7	0.0
Medians:	2.3	108.7	17.5	24.2	

Obviously, we would love to see a repeat of the massive outperformance of Value over Growth in the years that followed March 2000...




...even as we understand that multiples are nowhere near as outrageous today as they were back then.




There are still several expensive names in today's NASDAQ, but we actually find six of the top ten stocks to be undervalued.

	Weighting	Price to	Price to	Price to	Dividend
Company	Percentage	Earnings	Sales	Book Value	Yield
Apple	8.3	18.4	3.9	6.5	1.
Alphabet	6.5	31.2	7.0	4.7	
Microsoft	6.3	31.9	7.0	7.4	1.9
Amazon	5.1	296.3	3.5	22.9	
Facebook	4.0	34.2	14.0	7.2	
Intel	2.1	13.8	3.5	3.0	2.
Cisco Systems	1.8	18.4	4.0	2.9	3.
Comcast	1.8	19.9	2.3	3.4	1.
Amgen	1.2	14.3	5.6	3.9	2.
Nvidia	1.1	49.3	12.6	18.5	0.
Averages:	3.8	52.8	2.5	8.0	1.
Medians:	3.0	25.6	4.8	5.6	1.

Of course, we like that periods of rising interest rates (the Fed raised the Fed Funds rate again last month)...



...and inflation rates historically have been quite favorable for the kind of Value-priced stocks that we have long favored on an absolute and, especially, on a relative basis.



None of the above is meant to be a guarantee that Value will again have its day in the sun, though we might add that Value stocks are generally higher tax payers, but we remain confident that our style of investing, which should resonate logically with folks who generally hunt for bargains in their everyday lives, will continue to be fruitful.



Despite enduring two-dozen market pullbacks of at least 12% since its launch in 1977, *The Prudent Speculator* tops the Hulbert rankings.


			Price Return				Price Return
Start Date		End Date	%	Start Date		End Date	%
11.03.15	to	02.11.16	-13.3	03.24.00	to	04.04.01	-27.8
05.21.15	to	08.25.15	-12.4	07.16.99	to	10.15.99	-12.1
04.29.11	to	10.03.11	-19.4	07.17.98	to	08.31.98	-19.3
04.23.10	to	07.02.10	-16.0	07.16.90	to	10.11.90	-19.9
01.06.09	to	03.09.09	-27.6	10.21.87	to	12.04.87	-13.3
11.04.08	to	11.20.08	-25.2	08.25.87	to	10.19.87	-33.2
05.19.08	to	10.27.08	-40.5	10.10.83	to	07.24.84	-14.4
10.09.07	to	03.10.08	-18.6	11.30.81	to	08.12.82	-18.9
11.27.02	to	03.11.03	-14.7	11.28.80	to	09.25.81	-19.7
08.22.02	to	10.09.02	-19.3	02.13.80	to	03.27.80	-17.1
01.04.02	to	07.23.02	-32.0	09.12.78	to	11.14.78	-13.6
05.21.01	to	09.21.01	-26.4	12.31.76	to	03.06.78	-19.1
						AVERAGE	-20.6

Hulbert's Newsletter Rankings 30-Year Performance Scorecard							
Newsletter	Annualized						
Prudent Speculator, The	15.86						
Investment Reporter, The	12.86						
Fidelity Monitor & Insight	12.27						
Turnaround Letter, The	12.02						
Investment Quality Trends	11.98						
NoLoad FundX	11.69						
Bob Brinker's Marketimer	11.06						
PaulMerriman.com	7.27						
S&P 500 Total Return	10.70						
As of 12.31.17. Source: http://hulbertratings.com	/30-year-scoreboard/						

And we would argue that the Price to Book Value comparison between the Russell 3000 Value and Growth indexes makes a strong case that it may be time for Value to reassert its historical dominance,...



Believe it or not, despite the major market averages residing near record highs, Value stocks (as represented by the Russell 3000 Value index) trade at a lower-than-normal (over the past 22 years) price to book value ratio AND the valuation gap with Growth stocks (Russell 3000 Growth index) is as wide today as it has been since 2000.




...while the latest excessively bullish sentiment numbers from the American Association of Individual Investors, which would suggest that returns for stocks in the near term are likely to be subdued,...

THE PRUDENT SPECULATOR AAII Sentiment – Contrarian Indicator

Warren Buffett states, "Be greedy when others are fearful and fearful when others are greedy," and the weekly AAII Bull-Bear Spread and subsequent performance supports the Oracle of Omaha's assertion...at least on the "others are fearful" argument. Of course, the latest +44.2 reading, one of the highest ever, argues for a little near-term caution.

AAII Investor Sentiment Survey					AAII	Bull-Bear	Spread					
ce 1507, AAI members have been answering the same simple question each week:		Low Reading	High Reading		R3K Next 1-Month	R3K Next 1-Month	R3K Next 3-Month	R3K Next 3-Month	R3K Next 6-Month	R3K Next 6-Month		
by you feel the direction of the market over the next six months will be up (bullish), no change (neutral) or down (bearish)?	Decile	of the Range	of the Range	Count	Arithmetic Average TR	Geometric Average TR	Arithmetic Average TR	Geometric Average TR	Arithmetic Average TR	Geometric Average TR		
The results are compiled into the AAII Investor Sentiment Survey, which offers insight into the mood of individual investors.	Below & Above Median Bull Bear Spread = 8.5											
	BELOW MEDIAN	-54.0	8.5	808	1.2%	1.0%	3.2%	2.8%	6.4%	5.6%		
Survey Results for Week Ending 1/3/2018 Data represents what direction members feel the	ABOVE MEDIAN	8.5	62.9	779	0.5%	0.4%	2.1%	1.8%	4.6%	4.29		
stock market will be in next 6 months.					Te	n Equal Grou	pings of 1517	Data Points				
HISTORICAL AVERAGE 38.3%	1	-54.0	-14.3	159	1.2%	1.0%	4.0%	3.4%	8.0%	6.6%		
59.8% +7.1 frecentings point though from the state of the	2	-14.3	-7.0	163	1.3%	1.2%	4.0%	3.6%	7.4%	6.89		
39.6%	3	-6.8	-1.0	157	1.7%	1.6%	3.3%	2.9%	6.7%	5.9%		
HISTORICAL AVERAGE SHAN	4	-0.7	3.4	156	1.1%	1.0%	2.4%	2.1%	5.6%	5.1%		
NEUTRAL ************************************	5	3.4	8.0	162	0.5%	0.4%	2.4%	2.2%	4.8%	4.2%		
24.7%	6	8.1	12.8	155	0.3%	0.3%	1.5%	1.2%	4.5%	4.0%		
HETORICAL AVERAGE 56.7%	7	12.8	17.0	163	1.0%	0.9%	2.9%	2.7%	6.1%	5.7%		
15 GO/	8	17.0	22.7	154	0.8%	0.7%	2.2%	2.0%	5.5%	5.0%		
15.6% 10000 10000 1000 1000 1000 1000 1000	9	22.9	30.8	159	0.3%	0.2%	2.3%	2.0%	4.7%	4.1%		
nvestor Sentiment Survey has become a widely followed measure of the mood of individual	10	30.8	61.7	158	0.1%	0.0%	1.2%	1.0%	2.1%	1.7%		

...also add to the case for Value.



Stock Updates

Chris Quigley takes a look at market-moving developments at three of our companies...

Researchers reported the discovery of two major vulnerabilities in **Intel** (INTC - \$44.74) chips this past week, sending shares sharply lower (though the stock recovered somewhat and finished the week down 3.2%) and leaving the chip-making giant and other computer manufacturers scrambling to respond. The first vulnerability, Meltdown, was discovered independently by researchers from the TU Graz (Technical University of Graz in Austria), Cerberus Security (a German security firm) and Project Zero (Google). Meltdown is a hardware vulnerability that allows a rogue process to read any part of the processor's mapped memory, regardless of permissions. The second, Spectre, was independently discovered by Project Zero

and independent researcher Paul Kocher. Spectre, like Meltdown, allows rogue processes to violate hardware security boundaries and with the added problem that the vulnerability extends to smartphones. It is believed that Meltdown can be mostly patched with software updates, while Spectre might turn out to be impossible to patch (i.e. a new processor would be the only fix). The researchers have a website with details and a Q&A section here: https://meltdownattack.com/.

Intel responded via press release, "Intel and other technology companies have been made aware of new security research describing software analysis methods that, when used for malicious purposes, have the potential to improperly gather sensitive data from computing devices that are operating as designed. Intel believes these exploits do not have the potential to corrupt, modify or delete data. Recent reports that these exploits are caused by a 'bug' or a 'flaw' and are unique to Intel products are incorrect. Based on the analysis to date, many types of computing devices — with many different vendors' processors and operating systems — are susceptible to these exploits. Intel is committed to product and customer security and is working closely with many other technology companies, including AMD, ARM Holdings and several operating system vendors, to develop an industry-wide approach to resolve this issue promptly and constructively."

While Intel's initial response broadly obfuscated the issues, finger-pointed at ARM and AMD as guilty parties too, and avoided any practical comparisons between Meltdown and Spectre, follow-up material, chiefly this white paper: https://newsroom.intel.com/wp-content/uploads/sites/11/2018/01/Intel-Analysis-of-Speculative-Execution-Side-Channels.pdf, explained more precisely the nature of the vulnerabilities and mitigation options. And both Apple (AAPL - \$175.00) and Qualcomm (QCOM - \$66.47) subsequently indicated that their devices and processors were also affected by Meltdown and Spectre.

Wall Street analysts had mixed responses to the revelations, with some vigorously defending INTC and others opting for a wait-and-see approach. We are in the latter camp. Interestingly, there were no analyst downgrades, though a few did slash price targets. We think that the vulnerabilities hit Intel harder than ARM and AMD because Intel makes more chips than those two firms, and that any sort of hardware recall requiring chip replacement could be extremely painful to the company. We think that a full hardware recall is a highly unlikely outcome (how do you recall almost all processors made in the last 10+ years?), with software or firmware (low-level software controls hardware components) fixes the most likely solution and easiest to deploy with very low cost. Indeed, many companies including **Microsoft** (MSFT - \$88.19) and Apple have already released patches that mitigate risks. As such, we have opted to leave our Target Price of \$51 unchanged and will update as necessary when information becomes available. Intel reports Q4 results on January 25.

Of course, many were up in arms over the revelation that Intel CEO Brian Krzanich sold most of his INTC stake late last year, even as the company was aware of the vulnerabilities. Certainly makes for interesting click-bait online...until one realizes that the shares were sold at prices ranging from \$44.05 to \$44.56 on November 29...versus the current \$44.74 price. Not a big difference, we know, but if the assertion is that Mr. Krzanich should still be holding those shares

and "suffering" with his fellow shareholders, I am sure he would gladly undo the trades and redo them at today's close, netting an extra \$500,000 when all was said and done.

Agrium (AGU) and Potash Corp completed an all-stock merger over the holiday weekend, with shareholders receiving shares of the combined entity, **Nutrien** (NTR - \$55.73), on January 2. Per the company, "As the world's largest provider of crop inputs and services, Nutrien plays a critical role in Feeding the Future by helping growers increase food production in a sustainable manner. With nearly 20,000 employees and operations and investments in 14 countries, Nutrien's crop inputs and services reach every major growing region of the world. Nutrien produces and distributes over 25 million tonnes of potash, nitrogen and phosphate products for agricultural, industrial and feed customers globally." Shareholders of Agrium received 2.23 shares of NTR for each common share held, while shareholders of Potash received 0.40 shares of NTR for each common share held.

"Today we are proud to launch Nutrien, a company that will forge a unique position within the agriculture industry," said Chuck Magro, President and CEO of Nutrien. "Our company will have an unmatched capability to respond to customer and market opportunities, focusing on innovation and growth across our retail and crop nutrient businesses. Importantly, we intend to draw upon the depth of our combined talent and best practices to build a new company that is stronger and better equipped to create value for all our stakeholders."

Nutrien noted multiple benefits to the merger. Operating Synergies are "expected to generate US\$500-million of annual operating synergies, primarily from distribution and retail integration, production and SG&A optimization, and procurement savings. We expect to achieve approximately US\$250-million of these synergies by the end of 2018 with the full annualized run-rate achieved by the end of 2019." In regard to Capital Allocation, NTR noted, "With major capacity expansion projects complete, expected proceeds from the divestiture of equity investments and significant cash flow generation capability, Nutrien will have flexibility to invest in focused growth initiatives and return excess capital to shareholders, while also prioritizing a strong investment grade credit rating profile."

Our Agrium shares have performed well since we first recommended them in July 2013, despite the choppy business environment for fertilizers, returning 58% including reinvested dividends (11.0% per annum), and we expect to continue to hold our Nutrien stake for the time being. While management offered some pro-forma data tidbits in the Nutrien Factbook (http://www.nutrien.com/sites/default/files/uploads/2018-

<u>01/Nutrien%20Fact%20Book%202018_low_res.pdf</u>), the company expects to release a full set of financials for the blended company at the same time as the fourth quarter results are announced on February 5. Thus far, we know that, "Subject to market conditions and Nutrien Board approval, Nutrien expects to establish a dividend payment similar to the previous Agrium level of dividends, adjusted for the number of Nutrien shares outstanding," meaning that a guess for the annual dividend rate would be \$1.57 or so, putting the yield at a very respectable estimated 2.8%. At present, our Target Price for NTR is \$62.

Walgreen Boots Alliance's (WBA - \$72.92) fiscal Q1 2018 results came in ahead of analyst estimates, with the company earning an adjusted \$1.28 per share (vs. \$1.27 est.) on revenue of

\$30.7 billion (vs. \$30.4 billion est.). WBA's share buybacks propped up earnings per share (by reducing the share count) and pharmacy margins remained weak. Investors were unimpressed, sending shares from \$75.09 at the close on Wednesday to as low as \$70.73 on Thursday, without making much of a recovery by the closing bell. On Friday, however, investors collectively decided the 5% sell-off punishment didn't fit the crime, and shares made up half of the losses, finishing the first trading week of 2018 no worse for the wear.

CEO George Fairweather commented on the results, "Overall in the quarter, we have delivered a strong business performance both in terms of adjusted profit and cash flow, which gives us a good foundation for what we expect to be a solid year. We are particularly pleased with continued growth in U.S. pharmacy volume and market share. We recognize, of course, that our GAAP numbers have been significantly impacted by some notable special items. We completed the \$5 billion share buyback program announced in June plus the additional \$1 billion expansion announced on our last earnings call. Of course, our other development was Rite Aid regulatory clearance in September. In October, we started to acquire our first stores. This has gone well and by the end of December, we have bought a total of 357 stores. Since the quarter end, we have announced our agreement to acquire a 40% minority stake in Guoda, a leading Chinese retail pharmacy chain with over 3,500 pharmacies across 70 cities. Although this transaction in the context of the group is relatively small, we believe it has significant potential for the future. We've also announced an agreement to reduce our investment in our wholesale partner, Guangzhou Pharmaceuticals Corporation, giving us a cash-on-cash return of 3.6 times. This will leave us with a 20% interest in this successful partnership. Both transactions are of course subject to regulatory approval and customary closing conditions."

Management raised the bottom end of its full-year 2018 guidance from a range of \$5.40 to \$5.70 to a range of \$5.45 to \$5.70. Although Walgreen had to bow to U.S. regulatory pressure and only purchase a portion of Rite-Aid stores (2,186 of them, to be exact), we think that the added footprint will help the company reach a broader section of U.S. consumers and give WBA the opportunity to take the battle to its competitors. We also like the firm's European footprint via its 2,822 Boots stores in the United Kingdom, Norway, Ireland, the Netherlands and Lithuania, while Mexico, Chile and Thailand account for an additional 1,900 international stores. Longterm, we believe WBA will benefit from robust growth rates on pharmaceutical products due to the aging of the U.S. and European populations, and think that the AllianceRx mail service pharmacy partnership with Prime Therapeutics will be fruitful, especially as the FEP (Federal Employee Program) contract kicks in early this year. WBA generates solid free cash flow and we expect the dividend payout (the yield is currently 2.2%) to continue to rise. Our Target Price has been nudged up to \$116.

FOR INFORMATION ON PRIVATE CLIENT MANAGED ACCOUNTS PLEASE CALL 512-354-7041 OR E-MAIL CCREED@AFAMCAPITAL.COM